Quantitative Concept – Page 9

Navigating Trumps tariffs for pharma

3 months ago talkbio0Tagged Biomechanical compliance, Financial cost, HTS, Import, tariffs

Import, Biomechanical compliance, Financial cost, tariffs, HTS

Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal

3 months ago talkbio0Tagged Keytruda, Metastatic to, Overall Survival, Triple Negative Breast Neoplasms, Trodelvy

Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival

AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer

3 months ago talkbio0Tagged Antibodies, Antibody-Drug Conjugates, AstraZeneca, Daiichi, deruxtecan-nxki, Enhertu, fam-trastuzumab, first-line therapy, HER2-positive metastatic breast cancer, pertuzumab, Progression-Free Survival, Sankyo

Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab

FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD

3 months ago talkbio0Tagged Age related macular degeneration, Diabetic Retinopathy, dosing, Extension, Eylea HD, Interval, Regeneron, Rejection, United States Food and Drug Administration

United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy

RFK Jr.’s FDA staff cuts claimed key user fee negotiators, threatening renewal talks with pharma: Reuters

3 months ago talkbio0Tagged Does speak, Drug Industry, Fees, HHS, Mediation, negotiators, Staff, United States Food and Drug Administration, user fee

United States Food and Drug Administration, Does speak, Staff, negotiators, HHS, Mediation, user fee, Fees, Drug Industry

UK approval brings GSK’s Blenrep back from the brink

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Approved, Blenrep, Cessation of life, dexamethasone, DREAMM-8, Multiple Myeloma, Risk, UK

UK, Approved, Multiple Myeloma, DREAMM-8, dexamethasone, Blenrep, Antibody-Drug Conjugates, Risk, Cessation of life

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

3 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire

3 months ago talkbio0Tagged Administration occupational activities, Agencies, assumes, Budgets, HHS, Leaked, Patient Protection and Affordable Care Act, Programs - Publication Format, proposal - intent, Subsidies

Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format

RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines

3 months ago talkbio0Tagged Autistic Disorder, Environment, HHS, Kennedy, RFK gene, Vaccines

Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS

Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg

3 months ago talkbio0Tagged Alarm device, Changing, Disease Outbreaks, drug safety, Icebergs, KAT5 wt Allele, Leadership, Policy, Previous, public health medicine (field), United States Food and Drug Administration, Vaccines, Visible

United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible